Shanghai Fosun Pharmaceutical (Group) Co Ltd 2019 SR
The report highlights Fosun Pharma's 2019 sustainability performance, focusing on innovation and internationalization. Key achievements include the launch of Han Li Kang, China's first biosimilar, and the continued global impact of its anti-malarial drug, Artesun, which has saved over 24 million lives. The company invested RMB 3.46 billion in R&D and RMB 124.83 million in environmental protection. Significant progress was made in energy and water efficiency, with intensities decreasing by 14.8% and 16.5% respectively. Social initiatives included the Rural Doctor Poverty Alleviation project and the Double Thousand Action for tuberculosis.
Company: Shanghai Fosun Pharmaceutical (Group) Co Ltd
Sector: Manufacturing
Country: China
Year: 2019
Type: SR
Pages: 122
Back to company
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Corporate Social Responsibility Report
The report highlights Fosun Pharma's 2019 sustainability performance, focusing on innovation and internationalization. Key achievements include the launch of Han Li Kang, China's first biosimilar, and the continued global impact of its anti-malarial drug, Artesun, which has saved over 24 million lives. The company invested RMB 3.46 billion in R&D and RMB 124.83 million in environmental protection. Significant progress was made in energy and water efficiency, with intensities decreasing by 14.8% and 16.5% respectively. Social initiatives included the Rural Doctor Poverty Alleviation project and the Double Thousand Action for tuberculosis.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Published
Mar 30, 2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees